10-K: MeiraGTx posts $81M revenue on Lilly deal

MeiraGTx reported $81.4M in 2025 revenue driven by a $75M Lilly upfront, narrowed its net loss to $114.2M, secured FDA Breakthrough for its xerostomia gene therapy, and extended liquidity into H2 2027 pending a $200M Hologen collaboration closing in Q2 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive: the Lilly upfront transformed 2025 results, regulatory designations de-risk key assets, and manufacturing is commercial-ready. Risks remain around debt obligations, reliance on Hologen closing, and milestone uncertainty.

Future Outlook

Management plans to complete enrollment of the pivotal-design Phase 2 AQUAx2 study (AAV-hAQP1) by April 2026, target a BLA filing in the first half of 2027 with potential approval around year-end 2027 and US launch in early 2028. Phase 3 for AAV-GAD in Parkinson’s is expected to initiate in the coming months. The Hologen collaboration is expected to close in Q2 2026 (remaining $95M upfront), with up to $230M JV funding for CNS programs. MeiraGTx will manufacture JJIM’s RPGR product commercially following successful PPQ and UK commercial MIA.

Industry Context

StockSavvy.ai notes that gene therapy leaders increasingly pair deep in-house manufacturing with selective partnerships to de-risk late-stage assets. MeiraGTx’s Lilly deal mirrors the sector’s pivot to ophthalmology post-Luxturna (Roche/Spark), while JJIM’s bota-vec advances XLRP competition. In CNS, AAV vectors (e.g., Voyager/Lilly) remain active; MeiraGTx’s RMAT for AAV-GAD and a Phase 3 start align with the broader push to validate CNS gene therapies. The Hologen JV reflects the growing role of AI in trial design and analytics.

Recommendation

The filing shows improved financials from partner cash, strong regulatory tailwinds, and commercial-ready manufacturing, but reliance on the Hologen closing, high-cost debt with near-term repayments, milestone dependency, and negative equity temper near-term risk/reward. A hold is warranted pending Phase 2/3 readouts and completion of the Hologen transaction.

Keywords

["gene therapy", "AAV-hAQP1", "Breakthrough Therapy", "RMAT", "xerostomia", "Parkinson’s disease", "AAV-GAD", "AIPL1", "LCA4", "Eli Lilly", "Johnson & Johnson Innovative Medicine", "botaretigene sparoparvovec", "RPGR", "manufacturing MIA", "PPQ", "Hologen AI", "Shannon Ireland", "London ATMP", "royalties", "milestones"]